Results 11 to 20 of about 206,338 (257)

Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors in Treatment of Advanced Triple-negative Breast Cancer

Zhongliu Fangzhi Yanjiu, 2021
Advanced triple-negative breast cancer(TNBC) has less treatments, shorter survival time and poorer prognosis than other subtypes of breast cancer. The rapid development of immunotherapy in recent years is expected to prolong the survival time of advanced
HUANG Shifen, LING Xiaoling
doaj   +1 more source

Study of endostatin, tumstatin and PEDF, the natural angiogenesis inhibitors, potential in avasculargenic therapy

Oftalʹmologiâ, 2014
Purpose: To evaluate the potential of endostatin, tumstatin and PEDF in avasculargenic therapy.Methods: The avasculargenic potential of the natural angiogenesis inhibitors was explored on the model of alkaline burn, attended with angiogenesis of cornea ...
V. G. Likhvantseva, E. V. Arutyunyan, A. I. Miroshnikov, A. Yu. Salihov, O. V. Belous, K. D. Kurtshalidze, R. S. Esipov, K. A. Bejrahova,, V. N. Stepanenko   +8 more
doaj   +3 more sources

The Vasohibin Family

Pharmaceuticals, 2010
Angiogenesis is regulated by the local balance between angiogenesis stimulators and inhibitors. A number of endogenous angiogenesis inhibitors have been found in the body. The origin of these inhibitors is mostly extrinsic to the vasculature.
Yasufumi Sato
doaj   +1 more source

Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma

IJU Case Reports, 2020
Introduction Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy.
Hiroki Hagimoto, Soki Kashima, Kazuki Doi, Shintaro Nakayama, Takanori Sano, Satoshi Imai, Tomihiko Yasufuku, Mototsugu Muramaki, Yuji Yamada   +8 more
doaj   +1 more source

Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis

Journal of Hematology & Oncology, 2016
Monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs) directed against the vascular endothelial growth factor (VEGF) or its receptors have been investigated in several studies for the treatment of advanced gastric cancer (GC). In the
Jing Yu, Yue Zhang, Lai-Han Leung, Lian Liu, Fan Yang, Xiaojun Yao   +5 more
doaj   +1 more source

Current clinical application progress in angiogenesis inhibitors

上海师范大学学报. 自然科学版, 2018
Inhibition of angiogenesis is an established modality of cancer treatment.We summarized angiogenesis inhibitors of three modalities:single-target,multi-target and broad-spectrum agents.We discussed the clinical efficacy of monoclonal antibodies,small ...
Lu Yu
doaj   +1 more source

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature

Frontiers in Cell and Developmental Biology, 2021
Aberrant regulation of angiogenesis involves in the growth and metastasis of tumors, but angiogenesis inhibitors fail to improve overall survival of pancreatic cancer patients in previous phase III clinical trials.
Xi Zhang, Yang Liu, Zhen Zhang, Juan Tan, Junjun Zhang, Hao Ou, Jie Li, Zewen Song   +7 more
doaj   +1 more source

Angiogenesis and angiogenesis inhibitors in paediatric diseases

European Journal of Pediatrics, 1992
Angiogenesis, the generation of new capillaries from existing blood vessels, is rarely observed in the healthy organism, but can present during various paediatric diseases. In this review, we describe recent progress in the understanding of pathological angiogenesis and approaches for an improved therapy of angiogenic childhood diseases.
Schweigerer, L., Fotsis, T.
openaire   +3 more sources

Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer – Narrowing the Gap Between Bench and Bedside

Frontiers in Immunology, 2022
Angiogenesis in metastatic castration-resistant prostate cancer (mCRPC) has been extensively investigated as a promising druggable biological process. Nonetheless, targeting angiogenesis has failed to impact overall survival (OS) in patients with mCRPC ...
Antonio Giovanni Solimando, Antonio Giovanni Solimando, Charis Kalogirou, Markus Krebs, Markus Krebs   +4 more
doaj   +1 more source

Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases

Frontiers in Immunology, 2019
Angiogenesis is facilitated by the proteolytic activities of members of the matrix metalloproteinase (MMP) family. More specifically, MMP-9 and MT1-MMP directly regulate angiogenesis, while several studies indicate a role for MMP-2 as well.
Gregg B. Fields, Gregg B. Fields
doaj   +1 more source